| Biomarker ID | 931 |
| PMID | 22615945 |
| Year | 2012 |
| Biomarker | Spondin-2 (SPON2) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with Gleason Score >=7 and 8 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Gleason Score (2-6), (7-8) and (9-10) |
| Type of Biomarker | Diagnostic |
| Cohort | For tissue analysis, 3 normal prostatic Tissue, 7 cancer adjacent normal, 44 adenocarcinoma and 10 Hyperplasia of prostate were used |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | Tissue Microarray |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | SPON2 |